Sponsor Dossier

Fresenius Kabi

Sponsor Dossier for Fresenius Kabi. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.

About

Fresenius Kabi is an Australian Private Company with ABN 39109383593, incorporated in NSW and currently active. The company has operated under previous business names including ADDMIX, PHARMATEL MANUFACTURING, and PHARMATEL ONCOLOGY.

Portfolio

Fresenius Kabi has 51 brands on the ARTG, of which 46 are indexable and 46 carry a Product Information document. 2 brands are PBS-listed, 2 have a PBAC outcome on record, and 3 have an AusPAR on record. Notable brands include ADDAVEN, AMIKACIN KABI, AMINOVEN, BENZYLPENICILLIN KABI, CEFEPIME KABI, CEFTAZIDIME KABI, CHLORHEXIDINE, COLAZIDE, COMPOUND SODIUM LACTATE, DEXMEDETOMIDINE KABI, ERTAPENEM, FLUCLOXACILLIN KABI.

Therapeutic focus

— Other: 15 brands — Infectious Disease: 13 brands — Gastroenterology: 10 brands — Pain Management: 5 brands — Haematology: 2 brands — Oncology: 2 brands — Neurology: 2 brands — Cardiology: 1 brand — Musculoskeletal: 1 brand

PBS footprint

2 brands are PBS-listed, with the latest PBS schedule date 2026-11-01.

Regulatory activity

The latest PBAC outcome is 2020-11-01, across 2 brands with a PBAC outcome on record. The latest AusPAR is 2020-02-18, across 3 brands with an AusPAR on record.

ABR record